FTC Intervenes in Teva-Amneal Dispute to Advocate for Patent Delisting

The Federal Trade Commission (FTC) has once again entered a patent dispute, this time presenting amicus brief to a New Jersey federal court. The dispute centers on patents for asthma inhalers, held by pharma giant Teva Pharmaceuticals. These particular patents have already been part of an FTC investigation, as it believes that they, along with over 100 additional ones, were improperly listed in a crucial federal database.

This move marks the continuation of FTC’s active involvement in patent rows, especially those concerning potential mishandling or mislisting of patents. While the specifics of the FTC’s arguments in the amicus brief are not publicly available at this time, it is clear that this case is another instance of the commission’s ongoing commitments to appropriate patent practices.

Details on the conflict between Teva Pharmaceuticals and its rival Amneal are limited, but it is apparent that the FTC is showing increased interest in the pharmaceutical patent landscape. With this recent intervention in the Teva-Amneal quarrel, the commission continues its efforts to enforce fair patent listing and thwart any potential abuses of the system.

For more precise details on this matter, please refer directly to the original article on Law360.